Abstract
Several drugs were found which influence absorption, metabolism, and excretion of digitoxin (Bazzano et al., 1970; Caldwell and Greenberger, 1971; Jeliffe and Blankenhorn, 1966; Solomon and Abrams, 1972). Substances like ion-exchange resins and charcoal interfere with absorption and enterohepatic recycling of Fig. 34.1 digitoxin and its metabolites. Other compounds, which are known to induce enzymes involved in drug metabolism like phenobarbital, phenytoin, and phenylbutazone (Jeliffe and Blankenhorn, 1966; Solomon and Abrams, 1972) increase digitoxin metabolism. So far, however, there is no evidence, that these interactions create a major clinical problem in digitoxin therapy. The failure to control tachyarrhythmic atrial fibrillation with digitoxin in a patient receiving rifampicin, ethambutol, and isoniazid because of tuberculosis of the lungs led us to further investigations on the assumed interaction between these drugs and digitoxin. The results of these studies will be reported.
Serum digitoxin during fifamicin therapy. In a patient (H. R. 8113518/73,59 years) suffering from tuberculosis of the lung and paroxysmal atrial fibrillation with resulting tachyarrhythmia absoluta, digitoxin therapy initially cound suppress atrial fibrillation. 4 –6 weeks after continuous treatment with 600 mg per day p.o, rifampicin paraoxysmal tachycardia was observed again by the patient and the reoccurrence of atrial fibrillation documented by ECG. After increase of the daily digitoxin dose t o 0,2mg p.o., atrrial fibrillatiion and tachycardia no longer occurred.
Supported by “Deutsche Forschungsgemeinschaft (SFB 30)”.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ashley, J.J., Brown, B.T., Okita, G.T., Wright, S.W.: The metabolites of cardiac glycosides in human urine. J. Biol. Chem. 232, 315–322 (1958)
Bazzano, G., Gray, M., Sansone-Bazzano, G.: Treatment of digitalis intoxication with a new steroid-binding resin. Clin. Res. 18, 592 (1970)
Bolt, H.M., Kappus, H., Bolt, M.: Rifampicin and oral contraception. Lancet 1280–1281
Caldwell, J.H., Greenberger, N.J.: Interruption of enterohepatic circulation of digitoxin by cholestyramine. 1. Protection against letal intoxication. J. Clin. Invest. 50, 2626–2637 (1971)
Doherty, J.E., Hall, W.H., Murphy, M.L., Beard, O.W.: New information regarding digitalis metabolism. Chest 59, 433–437 (1971)
Edwards, O.M., Courtenay-Evans, R.J., Galley, J.M., Hunter, J., Tait, A.D.: Changes in Cortisol metabolism following rifampicin therapy. Lancet 1974/VII, 549–551
Jeliffe, R.W., Blankenhorn, M.H.: Effect of phenobarbital on digitoxin metabolism. Clin. Res. 14, 160 (1966)
Kolenda, K.-D., Lüllmann, H., Peters, T.: Metabolism of cardiac glycosides studied in isolated perfused guinea-pig liver. Br. J. Pharmacol. 41, 661–673 (1971)
Kuschinsky, K.: Über die Bindungseigenschaften von Plasmaproteinen für Herzglycoside. Naunyn-Schmiedeberg’s Arch. Pharmakol. Exp. Pathol. 262, 388–398 (1969)
Lukas, D.S.: The pharmacokinetics and metabolism of digitalis in man. In: Storstein, O (ed.): Symposium on Digitalis. Oslo: Gyldendal Norsk Forlag 1973, pp. 84–102
Okita, G.T.: Metabolism of radioactive cardiac glycosides. Pharmacologist 6, 45 (1964)
Peters, U., Hausamen, T.U., Grosse-Brockhoff, F.: Therapie mit Digitoxin unter Kontrolle des Serum-Digitoxinspiegles. Dtsch. Med. Wochenschr. 99, 1701–1707 (1974)
Peters, U., Hausamen, T.U., Grosse-Brockhoff, F.: Einfluß von Tuberkulostatika auf die Pharmakokinetik des Digitoxins. Dtsch. Med. Wochenschr. 99, 2381–2386 (1974)
Peters, U., Grabensee, B., Hausamen, T.U., Fritsch, W.-P., Grosse-Brockhoff, F.: Pharmakokinetik von Digitoxin bei chronischer Niereninsuffizienz. Dtsch. Med. Wochenschr. 102, 109–115 (1976)
Repke, V.: Die Bis- und Monodigitoxoside des Digitoxigenins und Digoxigenins: Metaboliten des Digitoxins. Naunyn Schmiedeberg’s Arch. Pharmakol. 237, 155–170 (1959)
Scholtan, W., Schlossmann, K., Rosenkranz, H.: Bestimmung der Eiweißbindung von Digitalis-Präparaten mittels der Ultrazentrifuge. Arzneim. Forsch. 16, 109–118 (1966)
Solomon, H.M., Abrams, W.B.: Interactions of digitoxin with other drugs. Am. Heart J. 83, 277–280 (1972)
Storstein, L.: The influence of renal function on the pharmacokinetics of digitoxin. In: Storstein, O. (ed.): Symposium on Digitalis, Oslo: Gyldendal Norsk Forlag 1973, pp. 158–168
Talcott, R.E., Stohs, S.J.: Interactions of digitoxigenin and digoxigenin with cytochrome P 450. Res. Commun. Chem. Pathol. Pharmacol. 4, 723–732 (1972)
Watson, E., Tramell, P., Kaiman, S.M.: Identification of submicrogram amounts of digoxin, digitoxin and their metabolic products. Isolation by chromatography and preparation of derivatives for assay by electron capture detector. J. Chromatogr. 69, 157–163 (1972)
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1978 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Peters, U., Hausamen, T.U., Grosse-Brockhoff, F. (1978). Digitoxin Disposition Under Rifampicin Treatment. In: Bodem, G., Dengler, H.J. (eds) Cardiac Glycosides. International Boehringer Mannheim Symposia. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-66904-0_36
Download citation
DOI: https://doi.org/10.1007/978-3-642-66904-0_36
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-08692-5
Online ISBN: 978-3-642-66904-0
eBook Packages: Springer Book Archive